SG11201706515QA - 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders - Google Patents
1-heterocyclyl isochromanyl compounds and analogs for treating cns disordersInfo
- Publication number
- SG11201706515QA SG11201706515QA SG11201706515QA SG11201706515QA SG11201706515QA SG 11201706515Q A SG11201706515Q A SG 11201706515QA SG 11201706515Q A SG11201706515Q A SG 11201706515QA SG 11201706515Q A SG11201706515Q A SG 11201706515QA SG 11201706515Q A SG11201706515Q A SG 11201706515QA
- Authority
- SG
- Singapore
- Prior art keywords
- isochromanyl
- heterocyclyl
- analogs
- compounds
- cns disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706515QA true SG11201706515QA (en) | 2017-09-28 |
Family
ID=55456908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201806809QA SG10201806809QA (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
| SG11201706515QA SG11201706515QA (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201806809QA SG10201806809QA (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (en) |
| EP (2) | EP3256466B9 (en) |
| JP (3) | JP6657241B2 (en) |
| KR (1) | KR102601972B1 (en) |
| CN (2) | CN107531674B (en) |
| AU (1) | AU2016219253C1 (en) |
| CA (1) | CA2976095C (en) |
| DK (1) | DK3256466T3 (en) |
| EA (1) | EA201791804A1 (en) |
| ES (1) | ES2911910T3 (en) |
| HU (1) | HUE058698T2 (en) |
| IL (1) | IL253914B (en) |
| MX (2) | MX371404B (en) |
| MY (1) | MY188160A (en) |
| NZ (1) | NZ735011A (en) |
| PH (1) | PH12017501422A1 (en) |
| PL (1) | PL3256466T3 (en) |
| PT (1) | PT3256466T (en) |
| SG (2) | SG10201806809QA (en) |
| UA (1) | UA122222C2 (en) |
| WO (1) | WO2016130796A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102601972B1 (en) * | 2015-02-11 | 2023-11-13 | 선오비온 파마슈티컬스 인코포레이티드 | 1-Heterocyclyl Isochromanyl Compounds and Analogs for Treating Central Nervous System Diseases |
| MX371197B (en) * | 2015-02-11 | 2020-01-22 | Sunovion Pharmaceuticals Inc | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders. |
| US10196403B2 (en) | 2016-07-29 | 2019-02-05 | Sunovion Pharmaceuticals Inc. | Compounds and compositions and uses thereof |
| CA3032141A1 (en) | 2016-07-29 | 2018-02-01 | Vadim ALEXANDROV | Compounds and compositions and uses thereof |
| EA202090180A1 (en) | 2017-06-30 | 2020-05-26 | Чейс Терапьютикс Корпорейшн | COMPOSITIONS OF NK1-ANTAGONIST AND METHODS OF TREATING DEPRESSION |
| BR112020001433A2 (en) | 2017-08-02 | 2020-07-28 | Sunovion Pharmaceuticals Inc. | isochroman compounds and their uses |
| US11136304B2 (en) | 2019-03-14 | 2021-10-05 | Sunovion Pharmaceuticals Inc. | Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| CA2336254A1 (en) | 1998-06-30 | 2000-01-06 | Daniel James Koch | 5-ht1f agonists |
| SE9902267D0 (en) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| CN1705654A (en) * | 2001-11-08 | 2005-12-07 | 塞普拉科公司 | Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram |
| EP1831203A1 (en) * | 2004-12-21 | 2007-09-12 | F. Hoffmann-Roche AG | Chroman derivatives and uses thereof in the treatment of cns disorders |
| KR20080008378A (en) | 2005-04-22 | 2008-01-23 | 와이어쓰 | Chromane and chromene derivatives and uses thereof |
| EP1981499A1 (en) * | 2006-01-27 | 2008-10-22 | F.Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
| KR101103118B1 (en) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition for the treatment of premature ejaculation thereof |
| SG10201401661RA (en) | 2009-12-04 | 2014-07-30 | Sunovion Pharmaceuticals Inc | Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders |
| JP5715713B2 (en) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Soluble guanylate cyclase activator |
| AR090557A1 (en) | 2012-04-02 | 2014-11-19 | Orion Corp | ADIDENIC AGONIST IMIDAZOLIC DERIVATIVES a2 |
| WO2014106238A1 (en) * | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
| KR102601972B1 (en) * | 2015-02-11 | 2023-11-13 | 선오비온 파마슈티컬스 인코포레이티드 | 1-Heterocyclyl Isochromanyl Compounds and Analogs for Treating Central Nervous System Diseases |
-
2016
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/en active IP Right Grant
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 PL PL16708262T patent/PL3256466T3/en unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/en active Active
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/en active
- 2016-02-11 UA UAA201708945A patent/UA122222C2/en unknown
- 2016-02-11 MX MX2017010363A patent/MX371404B/en active IP Right Grant
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en active Application Filing
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/en unknown
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en active Active
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/en active Active
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/en active Active
- 2016-02-11 MX MX2020001157A patent/MX2020001157A/en unknown
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 EA EA201791804A patent/EA201791804A1/en unknown
- 2016-02-11 PT PT167082627T patent/PT3256466T/en unknown
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 ES ES16708262T patent/ES2911910T3/en active Active
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en unknown
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/en active Active
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en active Pending
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291533A (en) | Compounds and compositions comprising thereof for treating cns disorders | |
| HK1259453A1 (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| HK1255330A1 (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| RS60642B1 (en) | Compositions and methods for treating cns disorders | |
| HK1252978A1 (en) | Compounds for use in treating neuromuscular disorders | |
| RS60343B1 (en) | Compositions and methods for treating cns disorders | |
| RS61530B1 (en) | Compositions and methods for treating cns disorders | |
| IL279308A (en) | Methods for treating hepcidin-mediated disorders | |
| IL253914A0 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
| GB201620460D0 (en) | Side stream treatment for overflow |